C07K16/00

Dynamic human heavy chain antibody libraries
11578426 · 2023-02-14 · ·

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.

Anti-EGF like domain multiple 6 (EGFL6) antibodies

The invention relates to anti-EGF like domain multiple 6 antibody (anti-EGFL6 antibody) and cancer detection (or diagnosis) and treatment using the anti-EGFL6 antibody. The present invention creates anti-EGFL6 antibodies, particularly, a single-chain antibody fragments (scFv) and humanized antibody, which have ability in binding to EGFL6 and in inhibiting angiogenesis and cancer cell growth.

Humanized antibodies

Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.

Humanized antibodies

Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.

High-loading and alkali-resistant protein a magnetic bead and method of use thereof

Provided is a high-loading and alkali-resistant protein A magnetic bead. The magnetic bead can maintain chemical stability under pH 2-14 and has an immunoglobulin G (IgG) binding capacity greater than 50 mg/mL. Further provided is a method for purifying and/or detecting an immunoglobulin, comprising a step of contacting a sample containing the immunoglobulin with the high-loading and alkali-resistant protein A magnetic bead. The alkali-resistant protein A magnetic bead can realize rapid purification of immunoglobulin, saving about 80% of treatment time and reducing total purification costs by 50%. In addition, the alkali-resistant protein A magnetic bead has high alkali resistance. An alkaline method for in situ cleaning can be performed to regenerate the magnetic bead after use. The magnetic bead has rapid magnetic response and good dispersiveness, realizing rapid magnetic bead enrichment, cleaning, and elution. The magnetic bead facilitates automated, high-throughput, and large volume purification of a sample.

High-loading and alkali-resistant protein a magnetic bead and method of use thereof

Provided is a high-loading and alkali-resistant protein A magnetic bead. The magnetic bead can maintain chemical stability under pH 2-14 and has an immunoglobulin G (IgG) binding capacity greater than 50 mg/mL. Further provided is a method for purifying and/or detecting an immunoglobulin, comprising a step of contacting a sample containing the immunoglobulin with the high-loading and alkali-resistant protein A magnetic bead. The alkali-resistant protein A magnetic bead can realize rapid purification of immunoglobulin, saving about 80% of treatment time and reducing total purification costs by 50%. In addition, the alkali-resistant protein A magnetic bead has high alkali resistance. An alkaline method for in situ cleaning can be performed to regenerate the magnetic bead after use. The magnetic bead has rapid magnetic response and good dispersiveness, realizing rapid magnetic bead enrichment, cleaning, and elution. The magnetic bead facilitates automated, high-throughput, and large volume purification of a sample.

EXPRESSION OF SEQUENCE-ENGINEERED LAMBDA ANTIBODY LIGHT CHAINS
20230039447 · 2023-02-09 ·

Expression of lambda antibody light chain with non-native leader sequence, wherein light chain is sequence-engineered to restore native N terminus. Immunoglobulin lambda variable domain sequence comprising N terminal deletion for expression with non-native N terminal signal peptide.

POPULATION OF ANTIBODIES COMPRISING HOMOGENEOUS ANTIBODIES EACH HAVING LEFT-RIGHT ASYMMETRIC SUGAR CHAINS, AND METHOD FOR PRODUCING SAME

A population of antibodies including homogeneous antibodies in which N-linked complex sugar chains attached to asparagine (Asn) at position 297 of CH domains of Fc regions of two heavy chains on the left and the right of each antibody are sugar chains structurally different from each other is described as well as a method of producing the population of antibodies.

POPULATION OF ANTIBODIES COMPRISING HOMOGENEOUS ANTIBODIES EACH HAVING LEFT-RIGHT ASYMMETRIC SUGAR CHAINS, AND METHOD FOR PRODUCING SAME

A population of antibodies including homogeneous antibodies in which N-linked complex sugar chains attached to asparagine (Asn) at position 297 of CH domains of Fc regions of two heavy chains on the left and the right of each antibody are sugar chains structurally different from each other is described as well as a method of producing the population of antibodies.

FUSION PROTEIN OF Z-DOMAIN AND CALSEQUESTRIN, HAVING IMPROVED REACTIVITY, STABILITY, AND ANTIBODY RECOVERY, AND METHOD FOR ISOLATION AND PURIFICATION OF ANTIBODY USING SAME

The present disclosure relates to a fusion protein of Z-domain and calsequestrin having improved reactivity, stability, and antibody recovery, and a method of isolating and purifying antibodies using the same. Specifically, the present disclosure relates to: a nucleic acid encoding a fusion protein of Z-domain and calsequestrin having improved reactivity, stability, and antibody recovery; a recombinant expression vector including the nucleic acid; a host cell transformed with the recombinant expression vector; and a method of isolating and purifying antibodies by using the fusion protein of Z-domain and calsequestrin having improved reactivity, stability, antibody recovery, and purity.